Argus analyst Jasper Hellweg downgraded Biogen (BIIB) to Hold from Buy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen announces U.S. FDA granted Fast Track designation to BIIB080
- Organon acquires rights for Tofidence from Biogen
- Biogen’s Favorable Outlook: Navigating Regulatory Challenges and Safety Advantages Justify Buy Rating
- Biogen announces plans for new global HQ, innovation hub at Kendall Common
- Biogen call volume above normal and directionally bullish